Search Results

You are looking at 1 - 10 of 473 items for :

  • "supportive care" x
Clear All
Full access

Noopur S. Raje, Andrew J. Yee and G. David Roodman

not curable, increasingly more patients are living with MM for longer periods as survival improves. The focus has centered on maximizing quality of life for patients with MM. Improvements in supportive care will allow patients to gain the benefit of

Full access

Young D. Chang, Jae-Woo Jung, Ritika Oberoi-Jassal, Jongphil Kim, Sahana Rajasekhara, Meghan Haas, Joshua Smith, Vijay Desai, Kristine A. Donovan and Diane Portman

supportive care setting, it is not surprising that patient and family inquiries about purported cannabinoid benefits for common cancer-related symptoms, such as pain, nausea, and poor appetite, have become more frequent as medical marijuana programs have

Full access

Sharon Spencer

the practical aspects of dose delivery to a patient, successful outcome of patient treatments, and convenience to the staff delivering the treatment. Supportive Care All professionals caring for patients with H&N cancer should assess supportive

Full access

Amy A. Kirkham, Kelcey A. Bland, Holly Wollmann, Alis Bonsignore, Don C. McKenzie, Cheri Van Patten, Karen A. Gelmon and Kristin Campbell

dietitians is limited. Although exercise training can be beneficial during and after treatment, intervention during chemotherapy may be especially important as supportive care in managing treatment-related side effects. With respect to exercise during

Full access

supportive care were also examined. Results: nab-P was associated with significantly longer TTD than eribulin in HR+/HER2− MBC ( Table 1 ). Granulocyte colony-stimulating factor (G-CSF) and antiemetics were used less with nab-P in both HR+/HER2− and TN MBC

Full access

Michael H. Levy, Anthony Back, Costantino Benedetti, J. Andrew Billings, Susan Block, Barry Boston, Eduardo Bruera, Sydney Dy, Catherine Eberle, Kathleen M. Foley, Sloan Beth Karver, Sara J. Knight, Sumathi Misra, Christine S. Ritchie, David Spiegel, Linda Sutton, Susan Urba, Jamie H. Von Roenn and Sharon M. Weinstein

– 168 . 29 Levy MH . Supportive oncologypalliative care: what’s in a name? Semin Oncol 2005 ; 32 : 131 – 133 . 30 Khatcheressian J Cassel JB Lyckholm L . Improving palliative and supportive care in cancer patients . Oncology

Full access

Paolo Marchetti, Raymond Voltz, Carmen Rubio, Didier Mayeur and Andreas Kopf

minutes), and variable frequency. Outcomes In a cohort of 208 patients with cancer admitted for oncology inpatient supportive care from May 2002 to May 2004, 38% had 1 to 2 severe symptoms at hospital admission, 31% had 3 to 4 severe symptoms, 22

Full access

David C. Dale, Gordon C. McCarter, Jeffrey Crawford and Gary H. Lyman

Delivery of cancer chemotherapy is often limited by myelotoxicity, primarily neutropenia. As part of an effort to create a model to predict the risk of chemotherapy-induced neutropenia, we reviewed the reports of randomized clinical trials with more than 50 patients per arm in early-stage breast cancer (ESBC) and non-Hodgkin's lymphoma (NHL) published between 1990 and 2000. We observed that no hematologic toxicity data were reported in 39% and 34% of the ESBC and NHL trials, respectively. The remaining trials reported on hematologic toxicity in 16 different ways. When reported, rates of neutropenia, leukopenia, and hematotoxicity varied widely with the same and similar chemotherapy regimens. Dose-intensity data were not reported in 39% and 54% of ESBC and NHL trials, respectively. The majority of the remaining studies reported incomplete dose-intensity data such as percentages of patients completing all cycles or receiving a given percentage of planned dose intensity. Only 28% reported the mean or median relative dose intensity received by patients. Based on this review, we conclude that current practices for reporting chemotherapy treatments are inadequate for describing the risk of chemotherapy to patients or for quantitatively assessing the risk of treatment alternatives. We recommend that standard procedures for documenting and reporting hematologic toxicity and dose intensity in cancer chemotherapy trials be required for publication of chemotherapy trials.

Full access

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

Featured Updates to the NCCN Guidelines

Shaji K. Kumar, Natalie S. Callander, Jens Hillengass, Michaela Liedtke, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, Jason C. Chandler, Robert F. Cornell, Caitlin Costello, Yvonne Efebera, Matthew Faiman, Alfred Garfall, Kelly Godby, Leona Holmberg, Myo Htut, Carol Ann Huff, Yubin Kang, Ola Landgren, Ehsan Malek, Thomas Martin, James Omel, Noopur Raje, Douglas Sborov, Seema Singhal, Keith Stockerl-Goldstein, Carlyn Tan, Donna Weber, Alyse Johnson-Chilla, Jennifer Keller and Rashmi Kumar

therapy and providing adequate supportive care. Myeloma Therapy Myeloma therapy using bortezomib-containing regimens should be initiated as soon as possible to decrease the production of nephrotoxic clonal immunoglobulin. 48 Bortezomib

Full access

Shaji K. Kumar

. “Clinical trial designs are now incorporating MRD as a measurement, but it is not yet clear if MRD status should change therapy for current patients.” Supportive Care/Adjunctive Treatment Supportive care measures have helped improve outcomes for